Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...

Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is ...

Q4 2025 earnings call recap: 2026 revenue guidance, margin gains, CPT reimbursement catalyst, and consumables outlook—read now.

Bionano says it expects another quarter of revenue growth. The company makes genomic testing equipment. Bionano has been consistently unprofitable. Bionano said it expected revenue of $7.3 million to ...

The technology of San Diego-based Bionano technology offers what’s called optical genome mapping, which is an analysis of the genome that reveals structural variations in the DNA of one person ...

Bionano Genomics, Inc. today announced the Stratys ™ system for high throughput optical genome mapping (OGM) and VIA ™ software for visualization, interpretation and reporting of genome analysis for ...

Good day, and welcome to the Bionano Fourth Quarter and Full Year 2025 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb ...

Bionano Genomics Inc (BNGO) reports improved gross margins and cost management amid revenue declines, with promising growth ...